# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **₹279.4 Cr** Q3 FY'26 (-0.6%) · **₹949 Mn** 9M FY'26 (+47%) * **Stand-alone Hospital Revenue:** **₹221 Cr** Q3 FY'26 (-6%) * **Consolidated PAT:** **₹1.3 Cr** Q3 FY'26 (0.5%) (vs. -₹3 Cr, -1.1%) * Net Debt: ₹408 Cr group · ₹54.5 Cr stand-alone ## B. Revenue Growth * **Near-Term Revenue Pressure:** Consolidated and stand-alone revenues declined **6% YoY** in Q3 due to normalization at Shalby Advanced Technologies and year-end effects, despite strong underlying fundamentals. * **Strong Nine-Month Trend:** 9-month consolidated revenue posted **robust growth**, reflecting broad-based strength across segments and recovery momentum. ## C. Profitability Trends * **Significant Margin Recovery:** Consolidated EBITDA and PAT turned **profitable year-on-year**, driven by cost optimization, operating leverage, and improved product mix, despite lower top-line. * **Tax Efficiency Ahead:** Shalby Limited to benefit from **25% tax rate** under new MAT rules, with **material reduction in tax expenses** expected next quarter, supporting future profitability. * **Profitability Volatility:** Group tax rate remains elevated (~35%) due to losses in MedTech and PK segments, but **ETR expected to stabilize** as these businesses reach profitability. ## D. Balance Sheet & Cash Flow * **Debt Reduction Pathway:** Net debt expected to decline over next 12 months, supported by **strong EBITDA from hospital operations** and lower funding needs for implants. * **Capital Light Outlook:** **No major capex** planned across hospital or implant businesses, enhancing cash flow generation and de-risking balance sheet trajectory. --- # 2. Hospital & Patient Metrics ## A. Key Figures * **ARPOB:** ₹43,171 (+1% YoY) * **Payer Mix:** 35% self-pay · 35% insurance/TPA · 30% government * **Shalby International ARPOB:** ₹87,526 · 51% revenue from international patients ## B. Occupancy & Volume Trends * **Volume Pressure Easing:** Inpatient, outpatient, and surgical volumes declined due to temporary suspension of **2–3 major insurance contracts**, now re-signed, with patient flow recovering in January and current quarter. * **PK Healthcare Drag:** Occupancy down QoQ at PK due to lapsed insurance tie-ups; re-engagement pending **imminent NABH accreditation**. * **Sanar Hospital Ramp-Up:** Current occupancy at ~20 beds, with full-year average expected to reach **at least 40 beds**, ending significantly higher. * **Performance Beyond Occupancy:** Management stresses **average occupied beds and patient counts** are more meaningful than occupancy % amid ongoing bed additions and new hospital rollouts (e.g., Nashik). ## C. ARPOB & ALOS Dynamics * **ARPOB Resilience:** Slight YoY increase despite volume headwinds; structural support expected from **SOCE revisions**, **CGHS rate hikes**, and future **robotics-driven premiumization**. * **ALOS Compression:** Improved efficiency with shorter stays overall, though **critical care expansion** has lifted ALOS to ~4 days—slightly above industry average—due to higher medical/critical care mix. * **Clinical Investment Payoff:** Rising doctor costs reflect talent upgrades, with **positive operational impact expected soon**. * **Service Mix Shift:** Arthroplasty now **33% of procedures** (down from 95% 15 years ago), signaling successful diversification beyond core orthopedics. ## D. Profitability & Margin Outlook * **Margin Ladder Emerging:** Hospitals >10 years old achieve **EBITDA in the 20s**, while 5–10 year units at **~15%**, below **normalized 20% target**, indicating untapped operating leverage. * **Stand-Alone Profitability Lag:** Despite maturity and better data, Shalby **lags peers on profitability**, with full benefits of scale not yet realized. --- # 3. MedTech Segment Performance ## A. Key Figures * Consolidated MedTech Revenue: **₹303.8M (₹30.38 Cr)** Q3 FY'26 (+29%) · **₹234.9M (₹23.49 Cr)** Q3 FY'25 * Shalby MedTech India Revenue: **₹189.6 Mn** (+77%) * Shalby Global Technologies Revenue: **₹17.2 Mn** (+378%) * Shalby Advanced Technologies (USA) Revenue: **₹264.6 Mn** (stable) * Shalby International Revenue: **₹23.9 Cr** (-1%) * **Group International Revenue:** **₹17 Cr** (Shalby International: ₹10 Cr; others: ₹4 Cr) * Shalby MedTech EBITDA: **₹5.5 Mn** (from loss of ₹75.2 Mn) * Shalby Global Technologies EBITDA: **₹1.9 Mn** (from loss of ₹1.4 Mn) ## B. Regional & Business Unit Performance * **Explosive International Growth:** Shalby Global Technologies posted **strong triple-digit growth**, reflecting successful Southeast Asia expansion and distribution scaling. * **Domestic Momentum:** Shalby MedTech India delivered **robust double-digit growth**, driven by distribution reach, surgeon adoption, and rising implant consumption. * **USA Resilience:** Despite lower revenue share, U.S. operations remain a **high-margin stronghold**, contributing disproportionately to profitability. * **Mixed International Trends:** While group-level international revenue grew, Shalby International (Pakistan) saw **marginal decline**, and EBITDA positivity was delayed due to **management challenges**. ## C. Profitability & Strategic Progress * **EBITDA Breakeven Achieved:** The MedTech platform has turned **profitable at EBITDA level**, with all three major units reporting positive or sharply improved margins, signaling successful turnaround execution. * **Margin Recovery Underway:** EBITDA improvement driven by **operating leverage, cost discipline, and lower COGS**, with past capex now yielding returns and no major reinvestment needed for 2–3 years. * **Path to PAT Breakeven:** While not yet net profitable, PAT loss has **narrowed significantly from ~50% to ~25%**, with structural improvements supporting future bottom-line inflection. ## D. Product & Market Expansion * **Pipeline Momentum:** **5–6 new products launched in the past year**, enhancing revenue streams and supporting margin expansion across geographies. * **Global Regulatory Gains:** Recent approvals in **Malaysia and Argentina** for Unicondylar implants expand OUS footprint, aligning with goal to generate **60% of implants revenue from OUS by year-end**. --- # 4. Clinical & Capacity Expansion ## A. Key Figures * **Doctor Net Additions:** **22** new doctors (40 hired, 18 exited) * **Transplants Completed:** **32** in the quarter (29 kidney, 3 liver) * **Robotics Investment:** **5** orthopedic and **2** other specialty robots installed * **Capital Investment:** **Over ₹80 Cr** invested in last 8–9 months in robotics, diagnostics, and infrastructure * **Shalby Academy Output:** **320 students** enrolled; **17 AHA workshop batches** completed ## B. Doctor Hiring & Retention * **Strategic Talent Rebuild:** Net addition of doctors reflects active renewal of clinical leadership, particularly in Delhi, with underperformers replaced and new hires supported by technology and marketing. * **Performance Ramp-Up Underway:** New doctors show gradual improvement, with those hired 6–9 months ago now delivering positive outcomes, indicating stabilization post-prior management disruptions. * **Sustainable Talent Pipeline:** Shalby Academy and intern programs (e.g., **130 physiotherapy interns**) are institutionalizing talent supply across core clinical functions. * **Future Capacity Flexibility:** Up to **50 additional beds** feasible in Delhi NCR; no major capex in next 12 months, with investments shifting to 12–24 month horizon. ## C. Robotics & Infrastructure * **High-End Capex Driving Utilization:** Recent investments in robotics, diagnostics (including **imminent PET CT launch**), and radiation bunkers are enabling higher acuity care and operational ramp-up. * **Scalable Infrastructure Platform:** **5 existing bunkers**, with **2 more planned** in Mohali and Delhi NCR; current facilities in 5 cities support expanded service delivery. * **Ramp-Up to Unlock Volume Surge:** Management expects **60–70% higher workload capacity** from existing units due to technology and infrastructure upgrades, with benefits soon visible on the top line. ## D. Specialty Diversification * **Transplant Momentum Maintained:** Quarterly transplant volume aligns with targets, reinforcing Shalby’s position in high-complexity care despite prior disruptions at PK Healthcare. * **PK Healthcare Restructuring:** Specialty stabilization underway after BMT/liver team exits; diversification into **cardiology, pulmonology, and ENT** reduces concentration risk. * **Balanced Portfolio Taking Shape:** Oncology, cardiology, and critical care now each contribute **10–15% of revenue** and are growing at high double-digit rates, signaling successful clinical diversification. * **Strategic Shift to Organic Growth:** Franchisee model discontinued (Rajkot, Lucknow closed); focus now on organic expansion, including upcoming **Mumbai facility**, with emphasis on core specialties and clinical excellence. --- # 5. Supply Chain & Manufacturing ## A. Key Figures * **Implant Growth Rate:** **40%–60%** annual growth (sustained trajectory) * **COGM for Implants:** Reduced to **50%** of level five years ago * **In-House Implant Usage:** Increased to **70%–80%** in January from **15%–20%** previously * **Internal Consumption (up to Q3):** **20%–25%** of total implant usage ## B. Implant Production * **Robust Segment Expansion:** Implant business continues on a high-growth trajectory with strong double-digit momentum, underpinned by declining cost of goods and sustained R&D investment. * **Margin Enhancement:** Significant COGM reduction over five years has materially improved profitability in the implant segment. ## C. Inventory & Planning * **Supply Chain Recovery:** Resolution of prior capacity and availability constraints has enabled a sharp rise in in-house implant utilization, boosting operational control and scalability. * **Planning Capability Upgrade:** Hiring of **top-tier talent** has strengthened inventory and supply chain planning, allowing proactive identification and resolution of bottlenecks. * **Structural Industry Challenges:** Lead times, regulatory complexity, and SKU diversity remain inherent hurdles in implant supply chains, requiring advanced forecasting. ## D. Regulatory Approvals * **International Expansion Momentum:** Regulatory filings underway in **South Korea, Vietnam, and Iran**, with active market entry discussions in **Ethiopia, Paraguay, Sri Lanka, and Russia**. --- # 6. Risks & Healthcare Factors ## A. Doctor Attrition * **Selective Retention Over Cost Inflation:** Management opted not to match aggressive competitor incentives to retain **two doctors**, prioritizing **profitability** over short-term volume. * **Mixed Impact on Operations:** Patient volume declined due to loss of **two high-end doctors**, though performance from recent hires over the past 6–9 months is showing positive traction. * **Unit-Specific Dynamics:** Jaipur unit maintained strong performance despite doctor attrition, while Naroda faced disruption from a **sudden government mandate requiring a full-time cardiac surgeon**. * **Franchise Exit Rationalized:** Shift away from franchise model driven by patient preference for centralized, larger facilities over smaller satellite units. ## B. Insurance Disruptions * **Insurance Operations Resumed:** Business halted in Q2 due to lapsed rate negotiations after **3–4 years without revisions**; **revised rates are now secured** and online empanelment is being restored. * **Growth Headwind from Lost Tie-Ups:** **Three major insurance partnerships were discontinued**, creating a measurable drag on revenue; reinstatement could have boosted growth. * **Short-Term Volatility Expected:** Hiring delays and insurance disruptions contribute to margin variability, but are viewed as **manageable, sector-typical challenges**. ## C. Regulatory Delays * **Persistent External Risks:** Regulatory hurdles—impacted by **geopolitical factors**—remain a key constraint, alongside capacity limitations, delaying the $100M goal. * **Proactive Market Planning:** Company has **mapped strategic markets** and identified corresponding regulatory barriers and mitigation pathways. --- # 7. Guidance & Outlook ## A. Key Figures * **Volume Growth:** **Double-digit** expected next year * **ARPOB Growth:** **+5% to +6%** projected * **EBITDA Margin Guidance:** **18%–20%** normalized range expected · **23%–25%** achievable with **50% higher occupancy** * **Unit-Level Margin:** **~20%** current stabilization level ## B. Volume Growth * **Global Expansion Momentum:** Structured international rollout expected to accelerate growth over 12–14 months as regulatory approvals unlock commercial traction. * **Sustained Arthroplasty Leadership:** Volumes to remain in **20%–30% range** driven by high profitability and ARPOB, outpacing broader industry adoption trends. * **Stable Utilization Metrics:** ALOS anticipated to hold near current levels, with minor variability linked to **specialty mix shifts**. ## C. Margin Trajectory * **Clear Margin Roadmap:** Path to **18%–20% group-level EBITDA margins** is underway, supported by operational stabilization and leverage from technology investments. * **Leverage Inflection Ahead:** Implant business set to deliver **meaningful operating leverage** in coming quarters, boosting profitability and cash flow. * **Portfolio Resilience:** Corporate diversification expected to **smooth margin volatility**, with offsetting performance across units enhancing overall stability. ## D. Strategic Priorities * **Five-Pillar Growth Engine:** Strategy focused on **people development**, **implant portfolio expansion**, **customer segmentation**, **COGS reduction**, and **supply chain excellence** to fuel global scale. * **Geographic Focus Divergence:** India to sustain strong growth momentum; U.S. operations prioritizing **margin enhancement** and **deeper surgeon engagement**. * **Targeted Government Expansion:** Selective pursuit of accretive government contracts; PK Healthcare to expand access via **Haryana govt, CGHS, and ECHS tie-ups** post-NABH. * **No Franchise Push:** Franchisee model **not part of near-term plans**, with no significant investment allocated to this channel. * **Implant Business Ambition Intact:** **$100M revenue aspiration unchanged**, with long-term potential beyond, though no formal guidance issued. * **Breakeven Timing Unconfirmed:** PAT breakeven expected in **FY '27 or '28**, but no official timeline provided.